XML 30 R13.htm IDEA: XBRL DOCUMENT
v3.25.1

Convertible Notes with Warrants (November 2023 Financing) | 12 Months Ended
--- | ---
Dec. 31, 2024
Convertible Notes with Warrants (November 2023 Financing) [Abstract] |
Convertible Notes with Warrants (November 2023 Financing) |
(7) | Convertible Notes with Warrants (November 2023 Financing)
On November 21, 2023, the Company issued (i) senior unsecured convertible notes in an aggregate principal amount of $6,850,000, convertible into shares of common stock at a conversion price of $1.18 per share, (ii) Series A Warrants to purchase up to an aggregate of 5,805,083 shares of common stock at an exercise price of $1.18 per share, and (iii) Series B Warrants, together with the Series A Warrants, and, together with the convertible notes, to purchase up to an aggregate of 5,805,083 shares of common stock at an exercise price of $1.475 per share. The financing resulted in aggregate gross proceeds of $6,850,000, before $525,144 of transaction costs. The Notes accrue interest at a rate of 6.0% per annum, payable annually, in cash or shares of common stock at the Company’s option, and mature on November 21, 2025, unless earlier converted or redeemed. In November 2024, the Company paid $111,000 of accrued interest in cash and $300,000 accrued interest in common stock of 315,790 shares. The Notes are convertible into shares of common stock at the election of the holder at any time at an initial conversion price of $1.18. The Company has agreed not to issue or sell any equity securities of the Company at a price below the then-current conversion price for a period of 18 months after closing, subject to certain exceptions. Beginning six months after issuance, the Company may require holders to convert their Notes into conversion shares if the closing price of the common stock exceeds $2.36 per share for 10 consecutive trading days and the daily dollar trading volume of the common stock exceeds $1,000,000 per day during the same period and certain equity conditions described in the Notes are satisfied. The Notes provide for certain events of default, whereby each holder of Notes will be able to require the Company to redeem in cash any or all of the holder’s Notes at a premium of 115%. The conversion feature did not meet the requirements for separate accounting and is not accounted for as a derivative instrument. As of December 31, 2024, the Convertible Notes have not been converted into shares of common stock. The Warrants The Series A Warrants are exercisable immediately and expire five years from the date of issuance. The Company has the right to call the exercise of the Series A Warrants if the closing price of the common stock exceeds 200% of the Series A Exercise Price for 10 consecutive trading days and the daily dollar trading volume of the common stock exceeds $1,000,000 per day during the same period and certain equity conditions are satisfied. The Series B Warrants were exercisable immediately, together with the Series A Warrant Shares, and expired one year from the date of issuance. The Company had the right to call the exercise of the Series B Warrants if the closing price of the common stock exceeded 200% of the Series B exercise price for 10 consecutive trading days and the daily dollar trading volume of the common stock exceeded $1,000,000 per day during the same period, and certain equity conditions were satisfied. There is no established public trading market for the warrants and the Company does not intend to list the Warrants on any national securities exchange or nationally recognized trading system. The Series B Warrants expired in November 2024. The Series A Warrants and Series B Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock from which they are issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. The Series A and Series B Warrants were valued using the relative fair value method and the following Black-Scholes assumptions:
|  | Series A Warrants |  |  | Series B Warrants |
Expected term (in years) |  |  | 5 |  |  |  | 1 |
Risk‑free interest rate |  |  | 4.55 | % |  |  | 5.24 | %
Dividend yield |  |  | — | % |  |  | — | %
Expected volatility |  |  | 104.89 | % |  |  | 113.84 | %
Exercise price |  | $ | 1.18 |  |  | $ | 1.48 |
Stock price |  | $ | 0.95 |  |  | $ | 0.95 |
Black-Scholes value |  | $ | 0.55 |  |  | $ | 0.28 |
The November 2023 Financing proceeds of $6,850,000 net of $525,144 in transaction costs were allocated to the convertible notes and Series A and Series B Warrants using the relative fair value method. The valuation of the warrants was $2,219,165 and is recorded as a component of stockholders’ equity, and a total debt discount of $2,744,309. For the year ended December 31, 2024, the Company recognized total interest expense on the convertible notes of $1,603,575, including coupon interest expense of $411,001 amortization of debt discount and issuance costs of $1,192,574. The effective interest rate for the discount amortization was 32.3%. The Notes and accrued interest, net of unamortized discount costs was $5,406,228 and $4,258,179 as of December 31, 2024 and 2023, respectively. The fair value of the convertible notes at December 31, 2024 and 2023, calculated using a discounted cash flow analysis using Level 3 inputs, was $6,493,720 and $6,126,151, respectively.
|  | Stated Interest Rate |  |  | 2024 |  |  | 2023 |
Convertible Notes |  |  | 6% |  |  | $ | 6,850,000 |  |  | $ | 6,850,000 |
Accrued and unpaid interest |  |  |  |  |  |  | — |  |  |  | 44,525 |
Less unamortized discount and debt issuance costs |  |  |  |  |  |  | (1,443,772 | ) |  |  | (2,636,346 | )
Total Convertible Notes Payable |  |  |  |  |  | $ | 5,406,228 |  |  | $ | 4,258,179 |
Future principal payments under the Notes if the conversion feature is not exercised, net of unamortized debt discounts, are $6,850,000 payable in November 2025.

X
- References No definition available. + Details
Name: | femy_ConvertibleNotesWithWarrantsNovember2023FinancingAbstract
Namespace Prefix: | femy_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for information about convertible notes with warrants financing. + References No definition available. + Details
Name: | femy_ConvertibleNotesWithWarrantsNovember2023FinancingTextBlock
Namespace Prefix: | femy_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration